HBOC 201 clinical trials
Also written Hemopure and HBOC-201.
How each study uses HBOC 201 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HBOC 201 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Biopure Corporation (5) · Englewood Hospital and Medical Center (1)
Studies
Open first, then newest update. How each study uses HBOC 201 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening AnemiaEnrolling by invitationNot applicableEnglewood Hospital and Medical CenterNCT01881503Written as HBOC-201
- Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary RevascularizationCompletedPhase 2Biopure CorporationNCT00479895Written as Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
- Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary RevascularizationCompletedPhase 2Biopure CorporationNCT00317512Written as Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)
- Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb IschemiaTerminatedPhase 2Biopure CorporationNCT00300040Written as Hemoglobin glutamer 250 - bovine
- A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass SurgeryStatus unknownPhase 2Biopure CorporationNCT00301535Written as HBOC-201 (hemoglobin glutamer-250 bovine)
- A Single Site Safety and Tolerability Study of HBOC-201 in Trauma SubjectsStatus unknownPhase 2Biopure CorporationNCT00301483Written as Hemoglobin-based oxygen carrier-201 (HBOC 201)
Codes
What other systems call HBOC 201 · ClinicalTrials.gg INT003877
- MeSH (NLM) C096798HBOC 201Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1XQE66T19HHEMOGLOBIN GLUTAMER-250 (BOVINE)Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C096798 | HBOC 201 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1XQE66T19H | HEMOGLOBIN GLUTAMER-250 (BOVINE) | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.